Psychedelics

After attending the Psychedelic Science conference in 2010, hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), I began my training as an adherence rater with this organization, contributing reliability data in clinical trials for MDMA-Assisted psychotherapy for PTSD. Working in this capacity since 2013, including providing adherence training to other clinicians, I have received unique preparation for working with trauma utilizing a psychedelic-assisted treatment model. Most recently I participated as one of about fifty clinicians selected from across the United States to complete qualification to provide MDMA-Assisted Psychotherapy for PTSD which the FDA has designated as a Breakthrough Therapy. Pending final protocol approval, this status will allow the treatment to be offered under an Expanded Access designation, meaning individuals (who meet specific diagnostic criteria) may seek the treatment outside of the Phase 3 clinical trials now taking place at sites in the US, Canada, and Israel.

Research in the therapeutic potential of psychedelics is experiencing a renaissance. From studies on psilocybin for treatment-resistant depression and for treating anxiety in patients with terminal illness, to use of ayahuasca in treating addiction, studies worldwide show that these medicines have tremendous potential. They are part of a paradigm that is shifting away from daily pharmaceutical treatment of symptoms toward use as catalysts to assist a process of healing. In addition to helping people move past debilitating conditions, current research on psychedelics and the brain points to ways these substances might help disrupt default patterns of thinking and behaving, offering potential for expanded capacity for change and growth. When used judiciously with intention and care, psychedelics hold promise toward living with greater creativity, vitality, and connection.